|
|
|
|
|
|
|
|
|
Webinar: Operationalizing Adaptive Design for FDA's One-Trial Era
|
The FDA’s 2026 One-Trial pathway is changing how sponsors approach pivotal trial design. In this webinar, Veristat’s adaptive design experts explore the statistical frameworks, regulatory strategies, and practical considerations for building a defensible single pivotal trial. Hear a real-world case study demonstrating how adaptive design can reduce development timelines and costs while maintaining trial quality, offering insights for today’s clinical development teams. Click here to learn more.
|
|
|
|
|
|
|
|
Take The Guesswork Out Of Charcot-Marie-Tooth Disease Research
|
|
Guest Column | A conversation between Susan Ruediger and Clinical Leader executive editor Abby Proch
|
A new Charcot-Marie-Tooth guidance introduces practical recommendations to help sponsors design clearer, more patient-centered, regulator-ready trials.
|
|
|
|
|
|
Key Health Policy Priorities Shaping The Second Half Of 2026
|
|
Article | By Ana Amaris, ISPOR—The Professional Society for Health Economics and Outcomes Research
|
See late‑2025 policy actions, including international pricing agreements, new payment models, and global regulatory changes, while previewing key themes expected to shape 2026 health policy.
|
|
|
|
|
|
|
|
|
|
Simplify Investigational Drug Management
|
|
Datasheet | McCreadie Group
|
Streamline clinical trial pharmacy operations, slash manual documentation time, and maintain continuous audit readiness across complex studies.
|
|
|
|
|
|
|
|
|
|
Webinar: What’s Working in AI-Enabled Respiratory Trials: From Recruitment to Site Readiness
|
Respiratory clinical trials face growing challenges, from shrinking patient populations and complex protocols to competition for patients and sites. How can AI and digital solutions help? This webinar explores practical approaches to optimize study design, predict enrollment, reduce participant burden and detect emerging risks earlier. Discover how technology can support efficient, patient-centric trials while strengthening quality and execution. Click here to learn more.
|
|
|
|
|
|
|
|
Small Biotech Can Outsource The Work, But Not The Thinking
|
|
From The Editor | By Dan Schell, Chief Editor, Clinical Leader
|
Robert Goldman explains why small biotechs can outsource clinical trial work — but never accountability. His advice on CRO oversight and responsible AI adoption shows how lean sponsors can gain efficiency without surrendering the judgment needed to spot risks and protect their programs.
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Clinical Leader: |
|
|
|
|
